Accelerated Immunosenescence and Chronic Kidney Disease
NCT ID: NCT02116270
Last Updated: 2018-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
222 participants
INTERVENTIONAL
2013-09-30
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Influencing Risk of Progression of Chronic Kidney Disease
NCT03954470
Evaluation of the Renal Function in an Ultra-endurance Race.
NCT03136315
Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation
NCT06887075
Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B/5
NCT06825234
Pilot Medical Evaluation of the T50 Test
NCT03292029
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, data on aging of the immune system in chronic kidney disease remains incomplete. Furthermore, the determinants of immunosenescence are not also not known. It is possible that "uremic" factors help explain the phenotypic and functional changes of lymphocytes, as antigenic stimuli associated with repeated bio-compatible materials used in dialysis contact.
The purpose of this study is to describe the phenotypes of the immune system of renal and analyze the determinants of these changes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
Blood sample
3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Severe renal failure
Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
Blood sample
3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Peritoneal dialysis
Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
Blood sample
3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Hemodialysis
Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
Blood sample
3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient not opposed to the conservation of biological samples for scientific research
Exclusion Criteria
* Any history of immunosuppressive therapy (except steroids up to 5mg/day)
* History of cancer (except skin cancer) or treated hematological malignancy
* Infectious episode required hospitalization not older 3 months
* Hepatitis B or C infection
* HIV infection, active or inactive
* For dialysis patients: renal failure on dialysis for less than 3 months and/or have benefited from two techniques for renal replacement therapy in the last 6 months
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jamal BAMOULID, Doctor
Role: PRINCIPAL_INVESTIGATOR
CHU de Besançon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de néphrologie, CHU de Besançon
Besançon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRIS API/2012/28
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.